

ASX ANNOUNCEMENT

BENITEC BIOPHARMA (ASX: BLT; OTC: BTEBY)

18 May 2015

ADDITIONAL PATENT GRANTED FOR BENITEC'S HEPATITIS C PORTFOLIO IN THE US

- **US patent granted strengthening Benitec's ddRNAi-based hepatitis C portfolio until 2026**
- **Corresponding European patent application allowed**

Sydney, Australia: Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) is pleased to advise that the US Patent Office has granted the US Patent 8,993,530 entitled "RNAi expression constructs". The patent claims ddRNAi expression constructs comprising multiple shRNA sequences targeting hepatitis C, driven off a single promoter. This is the third US patent granted in this family, further strengthening the intellectual property protection for Benitec's hepatitis C program until 2026 in the United States.

In addition, Benitec advises that the European Patent Office (EPO) has allowed the corresponding patent application EP 09015950.0 in this patent family. This will be the first European patent to be granted in this family. According to European practice, the EPO will soon announce the grant of this application and set a deadline of nine months for third parties to oppose the patent. In the absence of any opposition, the patent will be granted.

For more information, please contact the persons below or visit the Company's website at www.benitec.com.

Company	Investor relations
Sakura Holloway Senior Vice President Corporate Development and IP Counsel Tel: +61 (2) 9555 6986 Email: SHolloway@benitec.com	Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au